SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NNVC - NanoViricides, Inc. -- Ignore unavailable to you. Want to Upgrade?


To: Kirk © who wrote (9580)12/29/2017 4:23:32 PM
From: donpat1 Recommendation

Recommended By
Kirk ©

  Respond to of 12873
 
I'd love to see a Glaxo (GSK) or Novartis/Alcon or the like get in on the next round of financing.

First and foremost as a validation and secondly for their $$$$$s.

Mind you, that UIC+ broad spectrum contribution was a validation of a sort!!



To: Kirk © who wrote (9580)12/29/2017 4:26:46 PM
From: mattstat  Read Replies (1) | Respond to of 12873
 
Sounds like a dire prediction Kirk. Worse than I would have proposed.



To: Kirk © who wrote (9580)12/29/2017 4:41:17 PM
From: HardToFind  Respond to of 12873
 
Until then, it probably says they don't trust the folks running it to not let the company go under and start again without the burden of us shareholders....
I wonder what the cost of maintaining the license on the product is...is it just $25K a month to TheraCour for lab expenses, or is there more the company has to pay to hold onto their rights?